INHA and tuberculosis: The Xpert MTB/XDR test enables precise drug selection for TB patients: if a katG mutation (high-level resistance) is detected, INH should be discontinued; if an inhA mutation (low-level resistance) is identified, high-dose INH (10–15 mg/kg) may be retained.